KEYLYNK-007: Nivolumab plus Olaparib for Patients with HRR Mutated Solid Tumors
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

KEYLYNK-007: Nivolumab plus Olaparib for Patients with HRR Mutated Solid Tumors

Sponsor: Merck Sharp & Dohme Corp.

Protocol MK-7339-007: A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer. Eligible patients will have a mutation in any one of the following genes: BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, or RAD54L.